Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-EGFRvIII CAR-T for Recurrent Glioblastoma
NCT07244666Phase 1Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Meta10-EGFRvIII in glioblastoma (GBM) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Adverse Events at 12 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
Meta10-EGFRvIII
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07244666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244666.